BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO
Acquisition expands Bimini's global soft tissue franchise, which already includes the PureGraft and Dermapose Fat Transfer Systems PLANO, Texas, March 28, 2023 /PRNewswire/ -- Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology for the plastic and reconstructive surgery field of use. "The...
New Study Reveals Clinical Instability Predicts Psychiatric Hospitalization
First study of its kind, based on real-world data from Holmusk's NeuroBlu Database, shows patients who score highest for severity and instability were 45% more likely to be hospitalized NEW YORK, March 28, 2023 /PRNewswire/ -- For patients with psychiatric conditions, illness severity and instability are key factors in predicting future risk of hospitalization, according to a new study...
Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment
SHANGHAI, March 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the results from its PADN series study during the Late-Breaking Clinical Science (LBCS) session of the second Technology and Heart Failure Therapeutics (THT 2023), with the presentation of its follow-up findings from PADN-5 study. As the first sham randomized controlled study to explore pulmonary...
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD). Pombiliti™...
PharmaBlock Receives 2023 ACS CMO Excellence in Green Chemistry Award
NANJING, China, March 28, 2023 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CDMO company focusing on innovative chemistry and low-carbon manufacturing, announced today that it has been selected as the winner of the 2023 CMO Excellence in Green Chemistry Award by the American Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable (GCI PR). This award honors...
Sirnaomics Announces 2022 Annual Results
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights Clinical development - The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with the majority (78%) of patients achieving histological clearance - Exceptional results for BCC trial...
Tigermed Reports Full Year 2022 Results
HANGZHOU, China, March 28, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its annual results for the year ended December 31, 2022 (the "Reporting Period"). This press release is for information...
Seegene declares to share Syndromic PCR technologies to prevent future pandemics
Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands. Formation of a collaborative global network to aggressively develop innovative syndromic PCR assays, challenging boundaries of PCR application. Affordable and accessible syndromic PCR tests to the public through Seegene One System....
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today...
Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement
Performance Highlights: During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable to owners of the parent was RMB 3.873 billion, with a year-on-year growth of 18.17%; The revenue from new products and sub-new products including Han Li Kang, Han Qu You,...
